Antonin Rollet de Fougerolles
Direktor/Vorstandsmitglied bei Walking Fish Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Akshay Vaishnaw | M | 61 | 18 Jahre | |
| Kris Thielemans | M | - |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 11 Jahre |
| Lewis Williams | M | 74 |
Walking Fish Therapeutics, Inc.
 Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | 6 Jahre |
| Sara Nochur | M | 63 | 18 Jahre | |
| Kevin Fitzgerald | M | 56 | 19 Jahre | |
| Tom Brennan | M | - |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
| Seenu Kothakota | M | - |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
| Mark Selby | M | - |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
| Sonja van Meirvenne | F | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 11 Jahre |
| Kevin J. Heyeck | M | - |
Chimeron Bio Corp.
 Chimeron Bio Corp. Medical SpecialtiesHealth Technology Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck. | - |
| Bernard Sagaert | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| Marijn Dekkers | M | 65 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 2 Jahre |
| Stella Xu | M | 53 |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | 5 Jahre |
| Momo Wu | M | - |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
| Gorka Fius | M | - |
Chimeron Bio Corp.
Chimeron Bio Corp. Medical SpecialtiesHealth Technology Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck. | 2 Jahre |
| Anne Xie | F | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| Chen Yijun | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| Fius Gorka/chimeron Bio/ | - | - |
Chimeron Bio Corp.
Chimeron Bio Corp. Medical SpecialtiesHealth Technology Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck. | - |
| Franklin Berger | M | 74 |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
| Vincent Brichard | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| Alexis Ji | M | - |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
| Carlo Heirman | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 11 Jahre |
| Afshin Safavi | M | - |
Chimeron Bio Corp.
Chimeron Bio Corp. Medical SpecialtiesHealth Technology Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck. | - |
| Alexandra Tolia | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| Steven A. Bossone | M | - | 14 Jahre | |
| Frank Kalkbrenner | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| Steffen Helmling | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 1 Jahre |
| Kenneth Wils | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | - |
| John Paul de Koning | M | 55 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 8 Jahre |
| Kenneth R. Chien | M | - |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 2 Jahre |
| Muthiah Manoharan | M | - | 21 Jahre | |
| Vincent Ossipow | M | 55 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 8 Jahre |
| Steve Liapis | M | 36 |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bo Jesper Hansen | M | 66 | 5 Jahre | |
| Peter John Fellner | M | 80 | 5 Jahre | |
| Mike Mason | M | 49 | 14 Jahre | |
| William John Jenkins | M | 77 | - | |
| Douglas J. Ringler | M | - |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 Jahre |
| Victor J. Dzau | M | 78 | 7 Jahre | |
| Kevin Starr | M | 61 | 15 Jahre | |
| Herman Waldmann | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 Jahre |
| Hilde Windels | F | 59 | 1 Jahre | |
| Patricia Allen | F | 62 | 7 Jahre | |
| Lutgart A. A. van den Berghe | M | 72 | - | |
| Susanna High | F | 56 | 9 Jahre | |
| Dinah Sah | M | 63 | 7 Jahre | |
| Andrea Corcoran | F | 61 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 Jahre |
| Barry Greene | M | 60 | 17 Jahre | |
| Peter J. Williams | M | 69 | 3 Jahre | |
| Cynthia Clayton | F | - | - | |
| Mark O’Mahony | M | 53 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 Jahre |
| Teresa Regan | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 Jahre |
| Donna M. Jarlenski | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 2 Jahre |
| Titus M. F. M. Plattel | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 Jahre |
| Jason Rhodes | M | 54 | 3 Jahre | |
| Rachel Meyers | M | - | - | |
| Lubomir Nechev | M | - | - | |
| Robert Zeldin | M | 61 | 3 Jahre | |
| Mary DeLena | F | 56 | - | |
| Kim Simonsen | M | 67 | 2 Jahre | |
| Dominique Tersago | M | 62 | 4 Jahre | |
| Johan Heylen | M | 56 | - | |
| Markus L. E. Ewert | M | 64 | - | |
| Aoife Brennan | M | 48 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 Jahre |
| Jorgen Wittendorff | M | - | 3 Jahre | |
| Jared Gollob | M | 60 | 11 Jahre | |
| Eric W. Raichle | M | - | - | |
| David M. Konys | M | - | - | |
| Gerrit Franciscus Landolt | M | 60 | 14 Jahre | |
| John W. Littlechild | M | 72 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 7 Jahre |
| Vincent J. Miles | M | 73 | - | |
| Thomas R. Ulich | M | 70 | 1 Jahre | |
| John Freund | M | 70 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| John Schmidt | M | 73 | 1 Jahre | |
| Wayne T. Hockmeyer | M | 79 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 Jahre |
| James L. Vincent | M | 84 | 5 Jahre | |
| Dan Kisner | M | 77 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 10 Jahre |
| Vicki Sato | M | 75 | 6 Jahre | |
| Thomas A. Shea | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 Jahre |
| Stephen William Bunting | M | 71 | - | |
| Ed M. Scolnick | M | 83 | 2 Jahre | |
| Stephen Hoffman | M | 70 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| James Niedel | M | 79 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 9 Jahre |
| Ian Smith | M | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 7 Jahre |
| Louis Vaickus | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 9 Jahre |
| Robert A. Millman | M | - | - | |
| John Berriman | M | 76 | 2 Jahre | |
| Victor E. Kotelianski | M | - | - | |
| Nagesh Mahanthappa | M | 59 | 5 Jahre | |
| Russell Greig | M | 71 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | 7 Jahre |
| Diane Carman | F | 55 | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 61 | 67,03% |
| Belgien | 30 | 32,97% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Antonin Rollet de Fougerolles
- Persönliches Netzwerk
